Abstract 2151
Background
Clinical trials evaluating treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with aromatase inhibitors (AI) or fulvestrant have shown promising clinical benefit in patients with advanced breast cancer. We evaluated real-world clinical outcomes and toxicity rates in patients with advanced breast cancer who received treatment with CDK4/6i in routine clinical practice.
Methods
We retrospectively reviewed medical records of patients with advanced hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer treated at Departments of Oncology-affiliated with the Hellenic Cooperative Oncology Group (HeCOG). All patients received hormonal therapy in combination with CDK4/6i as first-, second- or third-line of treatment and beyond. The primary end point was progression-free survival (PFS).
Results
From 07/2015 to 03/2019, 191 women were treated with CDK4/6i combined with endocrine therapy (median age: 52.2 years, postmenopausal 87, 45.5%); 86 (45%) patients received CDK4/6i in combination with AI and 105 (55%) with fulvestrant. CDK4/6i were administered as first-line treatment in 65 (34%) patients, second-line treatment in 39 (20.4%) and third-line and beyond in 83 (43.5%) patients. The median follow-up was 54.3 months (95%CI 43.0-61.2). The median PFS for patients who received first-line treatment was 18.7 months, second-line treatment 11.5 months and ≥3 lines of treatment 7.5 months. The median overall survival since the initiation of CDK4-6i treatment was 23.2 months (95% CI 20.4-30.3). The most common adverse events were neutropenia (100 patients, 52.4%) and fatigue (24, 12.6%). Grade 3-4 adverse events occurred in 55 (28.8%) patients, while 2 (1.0%) patients permanently discontinued treatment due to toxicity.
Conclusions
Among patients with HR-positive advanced breast cancer treated with CDK4/6i combined with endocrine, the estimated PFS was comparable to previously reported data. Treatment was well tolerated, with a low drug discontinuation rate.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hellenic Cooperative Oncology Group.
Funding
Hellenic Cooperative Oncology Group (HeCOG).
Disclosure
E. Fountzilas: Travel / Accommodation / Expenses: K.A.M ONCOLOGY / HEMATOLOGY; Travel / Accommodation / Expenses: Merck; Shareholder / Stockholder / Stock options: Deciphera. G. Aravantinos: Advisory / Consultancy: Novartis; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Roche Hellas; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Amgen; Advisory / Consultancy: Genesis Pharma; Advisory / Consultancy: Merck; Advisory / Consultancy: Pfizer. G. Fountzilas: Advisory / Consultancy: Pfizer; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Roche; Honoraria (self): AstraZeneca. E. Razis: Honoraria (self), Advisory / Consultancy: Novartis; Travel / Accommodation / Expenses: Genesis Pharmaceuticals; Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: , Bristol-Myers Squibb; Travel / Accommodation / Expenses: Genekor. All other authors have declared no conflicts of interest.
Resources from the same session
714 - The feasibility and efficacy of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian insufficiency in patient with malignant ovarian germ cell tumors
Presenter: Min Kyu Kim
Session: Poster Display session 2
Resources:
Abstract
1753 - Ex vivo cytotoxicity and in vivo antitumor activity of a novel highly selective STAT3 inhibitor YHO-1701 for ovarian and endometrial cancer
Presenter: Kosei Hasegawa
Session: Poster Display session 2
Resources:
Abstract
3739 - Mutational landscapes and tumor mutational burden expression in endometrial cancer
Presenter: Yingli Zhang
Session: Poster Display session 2
Resources:
Abstract
2109 - Clinical features and frequency of mismatch repair protein deficiency in ovarian clear cell and endometrioid carcinoma patients.
Presenter: Kazuhiro Takehara
Session: Poster Display session 2
Resources:
Abstract
4554 - Prospective study evaluating white adipose tissue inflammation and clinicopathologic features in endometrial cancer
Presenter: Lea Moukarzel
Session: Poster Display session 2
Resources:
Abstract
3645 - Cancer-specific survival with or without adjuvant chemotherapy in high-risk stage I endometrial cancer
Presenter: Jenny Ko
Session: Poster Display session 2
Resources:
Abstract
3394 - Pembrolizumab in Patients with MSI-H Advanced Endometrial Cancer from the KEYNOTE-158 Study
Presenter: David Omalley
Session: Poster Display session 2
Resources:
Abstract
3388 - Who drops out of cervical cancer screening? Results from the EDIFICE 6 survey
Presenter: Thibault de La Motte Rouge
Session: Poster Display session 2
Resources:
Abstract
2485 - Identification of a RNA-Seq Based Signature to Improve Prognostic for Uterine Sarcoma
Presenter: Jian-Guo Zhou
Session: Poster Display session 2
Resources:
Abstract
1049 - The Effect Of Multiple Interventions For Women At Risk For Cervical Cancer On Their Health Responsibility, Beliefs Regarding Cervical Cancer, And Having Screening: A Randomized Controlled Experiment
Presenter: Busra Altinel
Session: Poster Display session 2
Resources:
Abstract